Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPS-0373 in Spinocerebellar Degeneration
NCT07040137Phase 3Active, not recruiting
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Mar 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rovatirelin in spinocerebellar degeneration (SCD), sponsored by Kissei Pharmaceutical Co., Ltd.. Started Aug 2025; status: active, not recruiting.
02
Drugs
rovatirelin
03
Conditions
spinocerebellar degeneration (SCD)
Beyond the preview
Go deeper on NCT07040137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040137.